Pittsburgh, December 15, 2000 -- The Brain Tumor Center announces the availability of a new clinical trial at University of Pittsburgh Cancer Institute utlizing a novel chemotherapy agent called fenretinide. This oral medication chemically related to vitamin A may induce glioma cells to differentiate into non-dividing, less aggressive cells.

This clinical trial is open to adult patients with recurrent or progressive high-grade gliomas following radiation therapy. For more information, please call the study principal investigator David Schiff, M.D. at (412) 692-2600 or the study research coordinator Mark Wargo, R.N. at (412) 647-5369.